

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

|  |                                       |
|--|---------------------------------------|
| <b>SUBMISSION TYPE:</b>  | NEW ASSIGNMENT                        |
| <b>NATURE OF CONVEYANCE:</b>   | ASSIGNMENT                            |
| <b>CONVEYING PARTY DATA</b>  |                                       |
| <b>Name</b>  | <b>Execution Date</b>                 |
| ISIS Pharmaceuticals, Inc.   | 08/13/2009                            |
| <b>RECEIVING PARTY DATA</b>  |                                       |
| <b>Name:</b>   | Antisense Therapeutics Ltd.           |
| <b>Street Address:</b>   | 10 Wallace Avenue                     |
| <b>City:</b>   | Toorak, Victoria                      |
| <b>State/Country:</b>  | AUSTRALIA                             |
| <b>Postal Code:</b>  | 3142                                  |
| <b>PROPERTY NUMBERS Total: 1</b>   |                                       |
| <b>Property Type</b>   | <b>Number</b>                         |
| <b>Application Number:</b>   | 11666001                              |
| <b>CORRESPONDENCE DATA</b>   |                                       |
| <b>Fax Number:</b>   | (510)337-7877                         |
| <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>     |                                       |
| <b>Phone:</b>  | 510-337-7871                          |
| <b>Email:</b>  | dbarragan@quinelaw.com                |
| <b>Correspondent Name:</b>   | Quine Intellectual Property Law Group |
| <b>Address Line 1:</b>   | 2033 Clement Ave, Suite 200           |
| <b>Address Line 4:</b>   | Alameda, CALIFORNIA 94501             |
| <b>ATTORNEY DOCKET NUMBER:</b>   | 42-000900US                           |
| <b>NAME OF SUBMITTER:</b>  | Deborah Barragan                      |
| <b>Total Attachments: 1</b><br>source=42-000900US_Assignment_ISIS_To_Antisense#page1.tif |                                       |

CH \$40.00 11666001

ASSIGNMENT OF PATENT APPLICATION

SOLE

WHEREAS, ISIS Pharmaceuticals, Inc., of 1896 Rutherford Road, Carlsbad, California 92008, hereinafter referred to as "Assignor," holds assignments from inventors of the invention described and set forth in the below-identified application for United States Letters Patent:

Title of Invention: TOPICAL ADMINISTRATIONS OF ANTISENSE  
COMPOUNDS TO VLA-4 FOR THE TREATMENT  
OF RESPIRATORY CONDITIONS

Filing Date: January 7, 2008; US Application No.: 11/666,001;  
October 20, 2005; AU Application No.: 2005327506;  
October 20, 2005; CA Application No.: 2,584,614;  
October 20, 2005; EP Application No.: 05857292.6;  
October 20, 2005; JP Application No.: JP 2007-537071;  
October 20, 2005; NZ Application No.: 554277;


WHEREAS, Antisense Therapeutics Ltd., a corporation, located at 10 Wallace Avenue, Toorak, Victoria 3142, AUSTRALIA, hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignor, Assignor has assigned, and by these presents does assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and which claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignor further agrees that Assignor will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Dated: August 13, 2009

  
\_\_\_\_\_  
ISIS Pharmaceuticals, Inc.

SIGNATURE WITNESSED BY:

(1) Date: August 13, 2009

  
\_\_\_\_\_  
Signature of Witness